Quantcast
Last updated on April 18, 2014 at 8:37 EDT

Latest Verenium Corporation Stories

2011-11-03 07:00:00

SAN DIEGO, Nov. 3, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release 2011 third quarter financial results on Thursday, November 10, 2011 after market close. In conjunction with the release, the Company will host a conference call with live webcast on Thursday, November 10th at 5:00 p.m. ET. The call may be accessed by...

2011-10-20 07:00:00

SAN DIEGO, Oct. 20, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company developing and commercializing high-performance enzymes, today announced that it has entered into an agreement with Comerica Bank and the Export-Import Bank of the United States ("Ex-Im Bank") for two 18-month, secured revolving credit facilities totaling up to $13 million. These new credit facilities will allow the Company to borrow up to $10 million against its...

2011-10-05 07:00:00

BioCee, a Minnesota-based material science and industrial biotechnology company, announced today that it has signed an asset purchase and license agreement to access certain technology from Verenium Corporation, a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, for the development of an environmentally-friendly biological method of removing sulfur from oil and oil distillates Minneapolis, Minnesota (PRWEB) October 05, 2011...

2011-09-27 07:00:00

SAN DIEGO, Sept. 27, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company developing and commercializing high-performance enzymes, today announced that it retired its remaining secured 9% Notes through repurchase, leaving an aggregate of $34.9 million in principal amount of unsecured 5.5% Notes outstanding. To effect this repurchase of approximately $1.1 million in principal amount of its 9% Notes, the Company paid a total of $1.2 million in...

2011-09-01 07:00:00

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced James Levine, President and Chief Executive Officer, will present at two upcoming conferences. Mr. Levine will present at the upcoming Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011. The presentation is expected to begin at 1:35 p.m. ET...

2011-08-09 15:05:00

SAN DIEGO, Aug. 9, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported a summary of recent Company highlights and financial results for the second quarter and six months ended June 30, 2011. "I am very pleased with the progress we've made in terms of product revenues and partnership negotiations in the first half of the year," said James E. Levine,...

2011-08-02 07:00:00

SAN DIEGO, Aug. 2, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release 2011 second quarter financial results on Tuesday, August 9, 2011 after market close. In conjunction with the release, the Company will host a conference call with live webcast on Tuesday, August 9th at 5:00 p.m. ET. The call may be accessed by dialing...

2011-07-28 07:01:00

SAN DIEGO, July 28, 2011 /PRNewswire/ -- Verenium Corporation (NASDAQ: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced that it repurchased approximately $5.2 million in principal amount of its 5.5% Notes and approximately $3 million in principal amount of 9% Notes. "We are very pleased to have taken another important step toward creating a capital structure that is appropriate to support the continued growth and...

2011-06-29 07:00:00

SAN DIEGO, June 29, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced the signing of a lease agreement for new office and laboratory space in the Torrey Pines area of San Diego, CA. The lease is targeted to commence in the summer of 2012 following the build out of the new facility and the expiration of Verenium's current sublease, which was...

2011-06-27 07:00:00

SAN DIEGO and ST. LOUIS, June 27, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, and Novus International Inc., a leading manufacturer of animal and human nutrition and health products, today announced a strategic collaboration to jointly develop and commercialize a suite of new enzyme products from Verenium's late-stage product pipeline in the animal...